Biopharma Funding Contracted Last Year – And 2023 Will See The Squeeze Continue

Up To 300 Companies Could Seek New Funds This Year

 
• By Andrew McConaghie

Now the pandemic-era biotech boom is over, biopharma companies and investors are both adjusting their financing strategies to survive and even thrive in the new environment.

Scrip Perspectives 2023
After the boom years of 2020 and 2021, the environment turned difficult for many early-stage biotechs last year, and 2023 could be even more challenging. • Source: Shutterstock

More from Business

More from Scrip